Intellia Therapeutics

CompanyUnited StatesFounded 2014

Wikidata

Intellia Therapeutics develops 2 assets, the furthest in phase 3 (NTLA-2001 in familial amyloidosis). Mostly gene editing acting on TTR; based in the United States, founded in 2014.

2
Assets
Furthest stage
Phase 3
Raised
$85M
4
Trials
5
Signals

Pipeline

2
  • NTLA-2001

    CRISPR-mediated disruption of hepatic TTR reduces transthyretin production and subsequent amyloid deposition.

    Phase 3, Gene editing, TTR, familial amyloidosis, hereditary amyloidosis

  • Lonvoguran

    Disrupts KLKB1 in liver cells to reduce plasma kallikrein production.

    Stage not known, Gene editing

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials4
  • Funding rounds and grants2
  • Deals2
  • Signals6
  • Similar companies6

Intelligence